Alpha Tau Medical (DRTS) News Today

Alpha Tau Medical Ltd. (NASDAQ: DRTS) shares have recently retreated after the company disclosed insider selling, while mixed analyst signals are also weighing on sentiment. The stock remains near its 52-week high, but investors are focused on continued losses and the latest earnings-estimate reductions.

• Positive Sentiment: HC Wainwright raised its price target for Alpha Tau Medical to $16 from $15 and reiterated a “Buy” rating. The target remains above the recently referenced share price, indicating potential upside and providing some support for DRTS. HC Wainwright forecast for Alpha Tau Medical
• Positive Sentiment: DRTS recently reached a new 12-month high, reflecting strong investor momentum and optimism surrounding Alpha Tau Medical’s targeted alpha-radiation cancer therapy platform. Alpha Tau Medical reaches a new 12-month high
• Neutral Sentiment: Analyst coverage remains broadly favorable: five analysts rate the stock Buy, two rate it Hold and one rates it Sell, producing a consensus “Moderate Buy” rating. However, the average target price of $12.80 is below recent trading levels, suggesting valuation-related risk.
• Negative Sentiment: Chief Financial Officer Raphi Levy sold 17,730 shares at an average price of $14, generating proceeds of approximately $248,220 and reducing his ownership by 16.43%. Although the transaction was executed under a pre-arranged Rule 10b5-1 plan, the sale can pressure the stock by signaling insider profit-taking. Raphi Levy sells Alpha Tau Medical shares
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to a loss of $1.05 from a loss of $0.67 and trimmed its FY2027 estimate to a loss of $0.60 from a loss of $0.55. Quarterly 2026 and 2027 loss estimates were also lowered to $0.15 per share from $0.14, indicating expectations for prolonged losses despite the Buy rating and $16 target.
• Negative Sentiment: Alpha Tau Medical’s latest quarterly results missed expectations, with an EPS loss of $0.50 versus the projected $0.14 loss and revenue of $0.10 million versus the expected $0.14 million. The sizable earnings miss reinforces concerns about operating performance and near-term cash burn.